AbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday’s ABCL635 Phase 2 Trial Results
AbCellera Biologics Inc. advanced 9.7% in after-hours trade on Friday. The gain came after the company confirmed it will release ABCL635 Phase 2 results on Monday. Nasdaq will remain closed over the weekend.
